LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

LLY

1,054.27

-0.65%↓

JNJ

209.54

-2.29%↓

ABBV

223.9

-1.64%↓

UNH

334.13

-2.12%↓

AZN

91.41

-0.2%↓

Home・Aandelen Lijst・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

64.74 -5.21

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

58.9

Max

68.36

Belangrijke statistieken
By Trading Economics
Inkomsten	155M -24M
Verkoop	229M 256M
Winstmarge	-9.26
Werknemers	711
EBITDA	-546M -148M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	-1.39% downside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.3B 9.5B
Vorige openingsprijs	69.95
Vorige sluitingsprijs	64.74

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

11.5 / 12.23 Steun & Weerstand

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 dec 2025, 23:46 UTC

Marktinformatie

Gold Edges Higher, Aided by Fed Rate-Cut Prospects -- Market Talk

16 dec 2025, 23:38 UTC

Marktinformatie

Nikkei May Rise on Possible Bargain-Hunting Interest -- Market Talk

16 dec 2025, 22:35 UTC

Acquisities, Fusies, Overnames

Santos: Sale Delivered Cash, Reduced Future Decommissioning Exposure

16 dec 2025, 22:35 UTC

Acquisities, Fusies, Overnames

Santos Sold 43% Stake in Petrel Fields, 100% of Tern Fields to Eni Australia

16 dec 2025, 22:33 UTC

Acquisities, Fusies, Overnames

Santos: A$40M Upfront Consideration, Up to A$20M in Contingent Payments

16 dec 2025, 22:33 UTC

Acquisities, Fusies, Overnames

Santos Sold 43% Operated Interest in Mahalo JV to Comet Ridge

16 dec 2025, 22:32 UTC

Acquisities, Fusies, Overnames

Santos Divests Two Noncore Assets as Part of Portfolio Optimization

16 dec 2025, 22:25 UTC

Acquisities, Fusies, Overnames

Westgold's Indicative Timetable Points to Early February Completion

16 dec 2025, 22:24 UTC

Acquisities, Fusies, Overnames

Westgold: Divestment Aligns With Broader Corporate Strategy

16 dec 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Westgold: Deferred Payment Based on Performance Hurdles

16 dec 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Westgold Will Receive A$15M Cash, A$19.6M in Alicanto Shares

16 dec 2025, 22:23 UTC

Acquisities, Fusies, Overnames

Westgold to Receive A$30M Deferred Payment in Cash or Shares

16 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Westgold Divesting Noncore Operating Asset for A$64.6M

16 dec 2025, 22:22 UTC

Acquisities, Fusies, Overnames

Westgold Agrees to Sell Mt Henry-Selene Project to Alicanto Minerals

16 dec 2025, 21:53 UTC

Winsten

Lennar Misses Earnings Estimates. The Stock Is Dropping. -- Barrons.com

16 dec 2025, 21:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

16 dec 2025, 21:33 UTC

Acquisities, Fusies, Overnames

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- 2nd Update

16 dec 2025, 21:18 UTC

Acquisities, Fusies, Overnames

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- Update

16 dec 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Worthington Enterprises to Buy LSI Group for About $205M >WOR

16 dec 2025, 21:16 UTC

Winsten

Worthington Enterprises 2Q Sales $327.5M >WOR

16 dec 2025, 21:16 UTC

Winsten

Worthington Enterprises 2Q Adj EPS 65c >WOR

16 dec 2025, 21:16 UTC

Winsten

Worthington Enterprises 2Q EPS 55c >WOR

16 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Worthington Enterprises Agrees To Acquire Leading Metal Roof Components Manufacturer LSI Group >WOR

16 dec 2025, 21:05 UTC

Acquisities, Fusies, Overnames

Ecolab Closes Acquisition Of Ovivo's Electronics Ultrapure Water Business >ECL

16 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Warner to Reject Paramount Offer As Soon As Wednesday, Sources Say -- WSJ

16 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Warner Preparing to Tell Shareholders to Reject Paramount Offer -- WSJ

16 dec 2025, 20:54 UTC

Acquisities, Fusies, Overnames

Warner to Recommend Existing Netflix Deal, Sources Say -- WSJ

16 dec 2025, 20:44 UTC

Marktinformatie

Russia-Ukraine Peace Efforts Send Crude to Near 5-Year Low -- Market Talk

16 dec 2025, 20:04 UTC

Marktinformatie

U.S. Natural Gas Extends Weather-Driven Losing Streak -- Market Talk

16 dec 2025, 20:01 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

-1.39% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 67.5 USD -1.39%

Hoogste 85 USD

Laagste 48 USD

Gebaseerd op 9 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

9 ratings

Buy

Hold

Sell

Gebaseerd op 9 analisten die aandelenratings hebben gegeven aan Arrowhead Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.